Annexon, Inc. Stock Price, News & Analysis

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing therapies for neuroinflammatory diseases, has announced the granting of inducement awards to seven new non-executive employees. These equity awards were approved on October 10, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4).

The awards consist of options to purchase a total of 643,500 shares of Annexon common stock. The options have a ten-year term and an exercise price of $7.45 per share, which was the closing price of Annexon's stock on October 15, 2024. The options will vest over 4 years, with 25% vesting on the first anniversary of the grant date and an additional 1/48th vesting monthly thereafter, subject to continued employment.

Annexon, Inc. (Nasdaq: ANNX) will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting and the Eyecelerator conference at AAO. ANX007, a first-in-kind, non-pegylated antigen-binding fragment (Fab), is designed to block C1q locally in the eye with an intravitreal formulation.

Key highlights include:

• ANX007 demonstrated significant vision protection in standard and low light conditions
• Significant photoreceptor preservation was observed in the fovea region critical for visual acuity
• Phase 3 data from the ongoing ARCHER II pivotal program is expected in the second half of 2026

Presentations will be made by Dr. Rahul N. Khurana and Douglas Love at the respective events in Chicago, Illinois.

Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has granted stock options to six new non-executive employees under its 2022 Employment Inducement Award Plan. The equity awards, approved on September 13, 2024, comply with Nasdaq Listing Rule 5635(c)(4). In total, the new employees received options to purchase 1,015,000 shares of Annexon common stock. These options have a ten-year term and an exercise price of $7.20 per share, matching the closing price of Annexon's stock on the grant date. The options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly, subject to continued employment.

Annexon (Nasdaq: ANNX) will present analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA) at two major ophthalmology conferences. ANX007, a novel C1q-blocking Fab, demonstrated significant vision protection in standard and low light conditions, and preservation of photoreceptors in the fovea region. The company has initiated the Phase 3 ARCHER II pivotal trial, with data expected in the second half of 2026. Presentations will highlight ANX007's potential to be the first treatment to protect vision in GA, focusing on its mechanism of action and clinical results from the ARCHER trial.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on novel complement therapies for neuroinflammatory diseases, has expanded its senior leadership team with three key appointments:

1. Shikhar Agarwal, M.B.A. as SVP, Head of Commercial
2. Sunil B. Mehta, Pharm.D as SVP of Medical Affairs
3. Myoung Kim, Ph.D., M.A., M.B.A. as VP of Health Economics and Outcomes Research

These appointments aim to strengthen Annexon's commercial development for flagship programs in Guillain-Barré Syndrome (GBS) and geographic atrophy (GA). The new leaders bring extensive experience in product strategy, successful launches, and market development across various therapeutic areas.

Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has announced its participation in two upcoming investor conferences in September 2024. Douglas Love, the company's president and CEO, will engage in fireside chats at the following events:

1. Wells Fargo Healthcare Conference on September 4, 2024, at 9:30 a.m. ET in Boston, MA
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:05 p.m. ET in New York, NY

Live webcasts of both presentations will be available on the Annexon website under the 'Events & Presentations' section of the Investors page. Replays will be archived for 30 days following each presentation.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has announced the granting of inducement awards to two new non-executive employees. These equity awards, approved on August 15, 2024, were granted under the company's 2022 Employment Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

The new employees received options to purchase a total of 83,000 shares of Annexon common stock. These options have a ten-year term and an exercise price of $5.98 per share, which was the closing price of Annexon's stock on the grant date. The options will vest over 4 years, with 25% vesting on the first anniversary and an additional 1/48th vesting monthly thereafter, subject to continued employment.

Annexon (NASDAQ: ANNX) reported significant progress in its Q2 2024 portfolio and financial results. Key highlights include:

1. ANX005 for Guillain-Barré syndrome (GBS) showed accelerated patient recovery in a pivotal Phase 3 trial.

2. ANX007 for Geographic Atrophy (GA) initiated dosing in the ARCHER II registrational trial.

3. ANX1502, an oral C1s inhibitor, completed a bridging study to a twice-daily tablet formulation.

4. Strong financial position with $368.7 million in cash and investments as of June 30, 2024, providing runway into H2 2026.

5. Anticipated milestones include topline RWE data for ANX005 by year-end 2024, Phase 3 data for ANX007 in H2 2026, and proof-of-concept data for ANX1502 in Q4 2024.

Annexon Inc (ANNX) has initiated patient dosing in the global Phase 3 ARCHER II trial for ANX007, a C1q inhibitor targeting geographic atrophy (GA). The trial aims to evaluate ANX007's potential to protect vision in GA patients, with topline data expected in H2 2026. New data from the Phase 2 ARCHER trial showed:

1. Significant vision protection in standard and low light conditions
2. Structural protection in key retinal areas for visual acuity
3. Up to 60% protection of photoreceptors in the central fovea
4. 29% protection of photoreceptors across the full retinal field

ANX007 is the only GA therapy candidate to receive PRIME designation in the EU and Fast Track designation from the FDA. The Phase 3 trial will enroll approximately 630 patients, using best corrected visual acuity (BCVA) protection against ≥15-letter loss as the primary outcome measure.